公开(公告)号：US20130330724A1

公开(公告)日：2013-12-12

申请号：US13966996

申请日：2013-08-14

Applicant: Academia Sinica

Inventor： Yuan-Tsong Chen ,  Shuen-lu Hung ,  Wen-hung Chung ,  Jer-Yuarn Wu

IPC: C12Q1/68

CPC classification number: C12Q1/6881 ,  C12Q1/6883 ,  C12Q2600/156 ,  G01N33/94

Abstract: The present invention provides a method of predicting the risk of a patient for developing adverse drug reactions, particularly SJS or TEN. It was discovered that an HLA-B allele, HLA-B* 1502, is associated with SJS/TEN that is induced by a variety of drugs. The correlation with HLA-B* 1502 is most significant for carbamazepine-induced SJS/TEN, wherein all the patients tested have the HLA-B* 1502 allele. In addition, another HLA-B allele, HLA-B*5801, is particularly associated with SJS/TEN induced by allopurinol. Milder cutaneous reactions, such as maculopapular rash, erythema multiforme (EM), urticaria, and fixed drug eruption, are particularly associated with a third allele, HLA-B *4601. For any of the alleles, genetic markers (e.g., HLA markers, microsatellite, or single nucleotide polymorphism markers) located between DRB1 and HLA-A region of the specific HLA-B haplotype can also be used for the test.

Abstract translation: 本发明提供了一种预测患者发展不良药物反应（特别是SJS或TEN）的风险的方法。 发现HLA-B等位基因HLA-B * 1502与由各种药物诱导的SJS / TEN相关。 与HLA-B * 1502的相关性对于卡马西平诱导的SJS / TEN是最显着的，其中所有测试的患者具有HLA-B * 1502等位基因。 另外HLA-B等位基因HLA-B * 5801与别嘌呤醇诱导的SJS / TEN特别相关。 特别是与第三等位基因HLA-B * 4601相关的皮肤反应较轻，如斑丘疹，多形性红斑，荨麻疹和固定药物爆发。 对于任何等位基因，位于特异性HLA-B单倍型的DRB1和HLA-A区之间的遗传标记（例如HLA标记，微卫星或单核苷酸多态性标记）也可用于测试。

公开(公告)号：US08594999B2

公开(公告)日：2013-11-26

申请号：US13709495

申请日：2012-12-10

Applicant: Academia Sinica

Inventor： Wen-Lian Hsu

IPC: G06F17/27

CPC classification number: G06F17/21 ,  G06F17/273 ,  G06F17/276

Abstract: For relieving typing burdens caused by incorrect spellings, typing errors, unknown spellings, and characters with diacritical marks, and for enhancing a typing efficiency of a typist with some simplified techniques, several candidate generating methods are provided for assisting the typist to pick a candidate word from a list of generated candidate words, or for selecting a candidate word from said list of generated candidate words in an automatic-selection manner. A proper-designed user interface may also be utilized for implementing the candidate generating methods.

公开(公告)号：US08501597B2

公开(公告)日：2013-08-06

申请号：US13191798

申请日：2011-07-27

Applicant: Yuh-Jen Cheng ,  Ming-Hua Lo ,  Hao-Chung Kuo

Inventor： Yuh-Jen Cheng ,  Ming-Hua Lo ,  Hao-Chung Kuo

IPC: H01L21/20 ,  H01L21/36 ,  H01L21/00

CPC classification number: H01L21/0254 ,  H01L21/0237 ,  H01L21/02458 ,  H01L21/02642 ,  H01L21/02647 ,  H01L33/007 ,  H01L33/20

Abstract: A method of fabricating a group III-nitride semiconductor includes the following steps of: forming a first patterned mask layer with a plurality of first openings deposited on an epitaxial substrate; epitaxially growing a group III-nitride semiconductor layer over the epitaxial substrate and covering at least part of the first patterned mask layer; etching the group III-nitride semiconductor layer to form a plurality of second openings, which are substantially at least partially aligned with the first openings; and epitaxially growing the group III-nitride semiconductor layer again.

Abstract translation: 制造III族氮化物半导体的方法包括以下步骤：形成具有沉积在外延衬底上的多个第一开口的第一图案化掩模层; 在所述外延衬底上外延生长III族氮化物半导体层并且覆盖所述第一图案化掩模层的至少一部分; 蚀刻III族氮化物半导体层以形成多个第二开口，其基本上至少部分地与第一开口对准; 并再次外延生长III族氮化物半导体层。

公开(公告)号：US08481699B2

公开(公告)日：2013-07-09

申请号：US12610749

申请日：2009-11-02

Applicant: Kuo Ping Chiu

Inventor： Kuo Ping Chiu

IPC: C07H21/00 ,  G01N33/487

CPC classification number: C40B50/06 ,  C12N15/1093 ,  C12N15/66 ,  C40B40/06

Abstract: Multiplex barcoded Paired-End Ditag (mbPED) library construction for ultra high throughput sequencing is disclosed. The mbPED library comprises multiple types of barcoded Paired-End Ditag (bPED) nucleic acid fragment constructs, each of which comprises a unique barcoded adaptor, a first tag, and a second tag linked to the first tag via the barcoded adaptor. The two tags are the 5′- and 3′-ends of a nucleic acid molecule from which they originate. The barcoded adaptor comprises a barcode, a first polynucleotide sequence comprising a first restriction enzyme (RE) recognition site, and a second polynucleotide sequence comprising a second RE recognition site and covalently linked to the first polynucleotide sequence via the barcode. The two REs lead to cleavage of a nucleic acid at a defined distance from their recognition sites. The length of the adaptor is set so that the bPED nucleic acid fragment fits one-step sequencing.

Abstract translation: 公开了用于超高通量测序的多路复用条形码配对结束Ditag（mbPED）库构建。 mbPED库包含多种类型的条形码配对结束分析（bPED）核酸片段构建体，每个构建体包含独特的条形码适配器，第一标签和通过条形码适配器链接到第一标签的第二标签。 两个标签是来源于其的核酸分子的5'和3'末端。 条形适配器包括条形码，包含第一限制酶（RE）识别位点的第一多核苷酸序列和包含第二RE识别位点的第二多核苷酸序列，并经由条形码共价连接到第一多核苷酸序列。 两个RE导致在与其识别位点限定距离处的核酸裂解。 适配器的长度设定为使得bPED核酸片段适合一步测序。

公开(公告)号：US08460669B2

公开(公告)日：2013-06-11

申请号：US13106046

申请日：2011-05-12

Applicant: Shie-Liang Hsieh ,  Chi-Huey Wong ,  Tsui-Ling Hsu ,  Szu-Ting Chen

Inventor： Shie-Liang Hsieh ,  Chi-Huey Wong ,  Tsui-Ling Hsu ,  Szu-Ting Chen

IPC: A61K39/395 ,  A61K39/285

CPC classification number: C07K16/2851 ,  A61K2039/505 ,  C07K2317/56 ,  C07K2317/76 ,  C07K2319/30 ,  G01N2333/18 ,  G01N2333/185 ,  G01N2500/02 ,  Y02A50/386 ,  Y02A50/388 ,  Y02A50/39 ,  Y02A50/394

Abstract: Cellular receptors are identified that induce plasma leakage and other negative effects when infected with flaviviruses, such as dengue virus or Japanese encephamyelitis virus. Using fusion proteins disclosed herein, the receptors to which a pathogen, such as flavivirus, binds via glycan binding are determined. Once the receptors are determined, the effect of binding to a particular receptor may be determined, wherein targeting of the receptors causing a particular symptom may be targeted by agents that interrupt binding of the pathogen to the receptor. Accordingly, in the case of dengue virus and Japanese encephamyelitis virus, TNF-α is released when the pathogen binds to the DLVR1/CLEC5A receptor. Interrupting the DLVR1/CLEC5A receptor with monoclonal antibodies reduced TNF-α secretion without affecting secretion of cytokines responsible for viral clearance thereby increasing survival rates in infected mice from nil to around 50%.

Abstract translation: 鉴定当感染黄病毒如登革热病毒或日本脑炎病毒时诱导血浆渗漏和其它负面影响的细胞受体。 使用本文公开的融合蛋白，确定病原体（例如黄病毒）通过聚糖结合结合的受体。 一旦确定了受体，就可以确定与特定受体结合的作用，其中导致特定症状的受体的靶向可能被阻断病原体与受体结合的试剂所靶向。 因此，在登革热病毒和日本脑炎病毒的情况下，当病原体与DLVR1 / CLEC5A受体结合时，TNF-α被释放。 用单克隆抗体中断DLVR1 / CLEC5A受体降低TNF-α分泌，而不影响负责病毒清除的细胞因子分泌，从而将感染小鼠的存活率从零增加到约50％。

公开(公告)号：US08450190B2

公开(公告)日：2013-05-28

申请号：US12729698

申请日：2010-03-23

Applicant: Yuh-Jen Cheng ,  Ming-Hua Lo ,  Hao-chung Kuo

Inventor： Yuh-Jen Cheng ,  Ming-Hua Lo ,  Hao-chung Kuo

IPC: H01L21/20 ,  H01L21/36 ,  H01L21/31 ,  H01L21/469 ,  H01L21/302

CPC classification number: H01L21/0254 ,  H01L21/0237 ,  H01L21/0242 ,  H01L21/02458 ,  H01L21/02639 ,  H01L21/02642 ,  H01L21/02647 ,  H01L33/007

Abstract: Defect selective passivation in semiconductor fabrication for reducing defects.

Abstract translation: 半导体制造中缺陷选择性钝化以减少缺陷。

公开(公告)号：US08431708B2

公开(公告)日：2013-04-30

申请号：US12613770

申请日：2009-11-06

Applicant: Ta-Chau Chang ,  Chih-Chien Cho ,  Cheng-Chung Chang ,  Chi-Chih Kang ,  Zi-Fu Wang

Inventor： Ta-Chau Chang ,  Chih-Chien Cho ,  Cheng-Chung Chang ,  Chi-Chih Kang ,  Zi-Fu Wang

IPC: C07D209/82 ,  A61K31/454

CPC classification number: C07D401/14 ,  C09K11/06 ,  C09K2211/1029

Abstract: A compound of formula (I): in which R1-R8, A, B, X, Y, m, and n are as defined herein. Also disclosed is a method for detecting a cancer cell using a compound of formula I.

Abstract translation: 式（I）化合物：其中R 1 -R 8，A，B，X，Y，m和n如本文所定义。 还公开了使用式I化合物检测癌细胞的方法。

公开(公告)号：US08415453B2

公开(公告)日：2013-04-09

申请号：US11783927

申请日：2007-04-13

Applicant: Han-Chung Wu ,  Chin-Tarng Lin ,  De-Kuan Chang

Inventor： Han-Chung Wu ,  Chin-Tarng Lin ,  De-Kuan Chang

IPC: A61K38/04 ,  A61K9/127 ,  A61P35/00

CPC classification number: G01N33/57423 ,  A61K9/1271 ,  A61K47/62 ,  A61K47/6911 ,  A61K51/1234 ,  C07K7/08

Abstract: The invention provides nucleic acids, peptides, and antibodies for use in applications including diagnosis and therapy. The peptides target lung cancer and were identified by phage display. Targeting phage PC5-2 and synthetic peptide SP5-2 were both able to recognize human pulmonary tumor specimens from lung cancer patients. In SCID mice bearing NSCLC xenografts, the targeting phage was able to target tumor masses specifically. When the peptide was coupled to liposomes containing the anti-cancer drugs vinorelbine or doxorubicin, the efficacy of these drugs against human lung cancer xenografts was improved, the survival rate increased, and the drug toxicity was reduced.

Abstract translation: 本发明提供用于包括诊断和治疗在内的应用的核酸，肽和抗体。 这些肽靶向肺癌，并通过噬菌体展示鉴定。 靶向噬菌体PC5-2和合成肽SP5-2均能够识别来自肺癌患者的人肺肿瘤标本。 在携带NSCLC异种移植物的SCID小鼠中，靶向噬菌体能够特异性地靶向肿瘤块。 当肽与含有抗癌药物长春瑞滨或多柔比星的脂质体偶联时，这些药物对人肺癌异种移植物的疗效提高，存活率提高，药物毒性降低。

公开(公告)号：US20130084298A1

公开(公告)日：2013-04-04

申请号：US13644311

申请日：2012-10-04

Applicant: Academia Sinica

Inventor： HAN-CHUNG WU ,  Kuo-Hua Tung

IPC: A61K39/395 ,  C07K16/46 ,  G01N21/76 ,  A61P35/00 ,  G01N33/574 ,  C07K16/28 ,  C12N9/96

CPC classification number: C07K16/18 ,  C07K16/303 ,  C07K2317/73

Abstract: A purified monoclonal antibody, or an. antigen-binding portion thereof, which specifically binds to human clathrin heavy chain (CHC) is disclosed. The antibody, or antigen-binding portion, thereof, exhibits at least one, two, three, four, five, six, seven, or all eight of the following properties: (a) specifically binds to pancreatic adenocarcinoma cells; (b) binding to the cell surface and cytosol of cancer cells and tumor blood vessels; (c) internalized by CHC-expressing cells; (d) inhibiting tumor growth, invasion ability, migration, and angiogenesis; (e) inducing apoptosis in cancer cells and human umbilical vein endothelial cells; (f) inhibiting tumor growth and tumor blood vessels in pancreatic cancer in vivo; (g) suppressing epidermal growth factor, transferrin, and VEGF internalizations by cancer cells; and (h) suppressing hypoxia-inducible factor-1α expression and vascular endothelial growth factor secretion. Methods for inhibiting tumor cell growth and/or angiogenesis, and detecting cancer in a subject is also disclosed.

Abstract translation: 纯化的单克隆抗体，或 公开了与人网格蛋白重链（CHC）特异性结合的抗原结合部分。 抗体或其抗原结合部分显示出以下性质中的至少一种，二种，三种，四种，五种，六种，七种或全部八种：（a）特异性结合胰腺腺癌细胞; （b）结合癌细胞和肿瘤血管的细胞表面和细胞溶质; （c）通过表达CHC的细胞内化; （d）抑制肿瘤生长，侵袭能力，迁移和血管生成; （e）诱导癌细胞和人脐静脉内皮细胞凋亡; （f）体内抑制胰腺癌肿瘤生长和肿瘤血管; （g）抑制癌细胞的表皮生长因子，转铁蛋白和VEGF内化; 和（h）抑制低氧诱导因子-1α表达和血管内皮生长因子分泌。 还公开了抑制肿瘤细胞生长和/或血管发生以及检测受试者中的癌症的方法。

公开(公告)号：US08394619B1

公开(公告)日：2013-03-12

申请号：US13575457

申请日：2011-01-28

Applicant: Su-May Yu ,  Tuan-Hua David Ho ,  Hsion-Wen Kuo ,  Ng I-Son Wu ,  Chen-Wei Li ,  Yu-Ming Ju

Inventor： Su-May Yu ,  Tuan-Hua David Ho ,  Hsion-Wen Kuo ,  Ng I-Son Wu ,  Chen-Wei Li ,  Yu-Ming Ju

IPC: C07K1/00 ,  C07H21/02 ,  C12N9/38 ,  C12N1/20 ,  C12N15/00

CPC classification number: C12P19/02 ,  C12N9/2445 ,  C12P19/14 ,  C12P2203/00 ,  C12Y302/01021 ,  Y02P20/134

Abstract: A novel beta-glucosidase and nucleic acids encoding the beta-glucosidase. Also disclosed are cells, compositions, and methods relating to using the beta-glucosidase to convert ligocellulosic material to fermentable sugars.

Abstract translation: 一种新型β-葡糖苷酶和编码β-葡糖苷酶的核酸。 还公开了与使用β-葡糖苷酶将纤维素材料转化成可发酵糖有关的细胞，组合物和方法。